JPH01163114A - Hair tonic - Google Patents
Hair tonicInfo
- Publication number
- JPH01163114A JPH01163114A JP62323570A JP32357087A JPH01163114A JP H01163114 A JPH01163114 A JP H01163114A JP 62323570 A JP62323570 A JP 62323570A JP 32357087 A JP32357087 A JP 32357087A JP H01163114 A JPH01163114 A JP H01163114A
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- hair
- acid
- tonic
- bonded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 44
- 230000001256 tonic effect Effects 0.000 title claims abstract description 14
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 71
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 55
- 230000003779 hair growth Effects 0.000 claims abstract description 22
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 11
- 150000002482 oligosaccharides Chemical group 0.000 claims abstract description 11
- 235000013336 milk Nutrition 0.000 claims abstract description 8
- 210000004080 milk Anatomy 0.000 claims abstract description 8
- 239000008267 milk Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Chemical group 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 23
- -1 sialic acid salt Chemical class 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 208000001840 Dandruff Diseases 0.000 abstract description 4
- 230000005722 itchiness Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 12
- 201000004384 Alopecia Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000003676 hair loss Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000001913 submandibular gland Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical class OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000036068 sialic acid binding proteins Human genes 0.000 description 1
- 108091000315 sialic acid binding proteins Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- YRTWNFXASSUQEW-UHFFFAOYSA-M sodium;methanol;acetate Chemical compound [Na+].OC.CC([O-])=O YRTWNFXASSUQEW-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BDOBMVIEWHZYDL-UHFFFAOYSA-N tetrachlorosalicylanilide Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(=O)NC1=CC=CC=C1 BDOBMVIEWHZYDL-UHFFFAOYSA-N 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、新規な養毛材に関するものである。[Detailed description of the invention] [Industrial application field] The present invention relates to a novel hair nourishing material.
従来、禿や脱毛の原因としては、毛根、皮脂腺等の器官
における男性ホルモンの活性化、毛包への血流量の低下
、皮脂の分泌過剰、酸化物等の生成、細菌の繁殖等によ
る頭皮の異常、遺伝的要素、ストレス等による神経症、
疾病による二次的なものおよび老化等が考えられる。Traditionally, the causes of baldness and hair loss include activation of male hormones in organs such as hair roots and sebaceous glands, decreased blood flow to hair follicles, excessive secretion of sebum, production of oxides, and growth of bacteria on the scalp. Neurosis caused by abnormalities, genetic factors, stress, etc.
Possible causes include secondary to disease and aging.
このため、従来の養毛剤には、前記の原因を取り除いた
り、又は軽減する作用をもつ化合物が一般に配合されて
いる。例えば、ビタミンB等のビタミン類、メチオニン
等のアミノ酸類、アセチルコリン誘導体等の血管拡張剤
、紫根エキス等の抗炎症剤、エストラジオールなどの女
性ホルモン剤、セファランチンなどの皮Ji’jla能
冗進剤などが配合され、脱毛症の予防及び治療に用いら
れている。For this reason, conventional hair growth agents generally contain compounds that have the effect of eliminating or alleviating the above-mentioned causes. For example, vitamins such as vitamin B, amino acids such as methionine, vasodilators such as acetylcholine derivatives, anti-inflammatory agents such as purple root extract, female hormones such as estradiol, skin-stimulating agents such as cephalanthine, etc. It is used in the prevention and treatment of alopecia.
しかしながら、脱毛や発毛のta構は非常に複雑であり
、単に男性ホルモンの活性化を阻害したり、毛包の血流
■を増加させるだけでは禿や脱毛を充分に防止すること
はできない。従来の養毛剤は一部の人に対してのみ、フ
ケ、カユミ、(u毛の予防又は改善効果が認められてい
るが、今だ満足すべき発毛、育毛促進又は脱毛防止効果
を発揮するものは得られていない。However, the mechanism of hair loss and hair growth is extremely complex, and baldness and hair loss cannot be sufficiently prevented simply by inhibiting the activation of male hormones or increasing blood flow to hair follicles. Conventional hair restorers have been shown to be effective in preventing or improving dandruff, itching, and hair loss for only some people, but they still do not have satisfactory effects on hair growth, promoting hair growth, or preventing hair loss. has not been obtained.
本発明者等は、上記の事情に鑑み、脱毛に対して有効で
あり、優れた養毛効果を持つ物質を得るべく鋭意研究を
重ねた結果、シアル酸並びにシアル酸誘導体に優れた養
毛効果を有することを見出し、本発明を完成するに至っ
た。In view of the above circumstances, the present inventors have conducted extensive research to obtain a substance that is effective against hair loss and has an excellent hair-nurturing effect. The present invention was completed based on the discovery that the present invention has the following properties.
即ち、本発明はシアル酸及びシアル酸誘導体より成る群
から選択された一種又は二種以上を含有してなる養毛剤
を提供するものである。That is, the present invention provides a hair nourishing agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に用いられるシアル酸は公知の物質であり、ポリ
ヒドロキシモノアミノカルボン酸(ノイラミン酸)のN
−アシル及びN−アシル、0−アシル銹導体の総称で、
シアリン酸とも言われる。The sialic acid used in the present invention is a known substance, and the N of polyhydroxymonoaminocarboxylic acid (neuraminic acid)
- A general term for acyl, N-acyl, and 0-acyl conductors,
Also called sialic acid.
シアル酸は各種の生物に含まれ、通常細胞表層糖質を構
成して糖タン白質や糖脂質の末端にグリコシド結合して
存在する。特に脳、神経、血液、顎下腺、ムチン質、初
乳に多(は存在するが、遊離して血清や体液、尿中にも
存在する。生物界にいちばん多く見出される代表的なシ
アル酸はN−アセデルノイラミン酸(NANA:分子Q
309)で、融点185〜187℃、[α]’f−3
2°±2°の白色粉体である。Sialic acid is contained in various organisms, and usually constitutes cell surface carbohydrates and exists in glycosidic bonds at the terminals of glycoproteins and glycolipids. It is particularly abundant in the brain, nerves, blood, submandibular glands, mucin, and colostrum, but it is also present in free form in serum, body fluids, and urine.A typical sialic acid found most abundantly in living organisms. is N-acedelneuraminic acid (NANA: molecule Q
309), melting point 185-187℃, [α]'f-3
It is a white powder with an angle of 2°±2°.
シアル酸並びにシアル酸誘導体の生物学的薬理作用は細
胞表面の陰性荷電への寄与、細胞の特異的認識機構への
関与、ウィルスによる赤血球既築反応や血液タンパク質
のホーミング現象等に関することが知られている。最近
では、シアル酸について去痰活性(特開昭61−684
18) 、抗炎症効果(特開昭62−145015)並
びにシアル酸結合オリゴ糖の栄養効果(特開昭61−1
52233)等の報告がなされている。The biological and pharmacological actions of sialic acid and sialic acid derivatives are known to be related to their contribution to negative charge on the cell surface, their involvement in specific cell recognition mechanisms, the red blood cell pre-existing reaction caused by viruses, and the homing phenomenon of blood proteins. ing. Recently, expectorant activity of sialic acid (Japanese Patent Application Laid-Open No. 61-684
18) Anti-inflammatory effect (Japanese Patent Application Laid-open No. 62-145015) and nutritional effect of sialic acid-binding oligosaccharides (Japanese Patent Application Laid-open No. 61-1
52233) etc. have been reported.
しかしながら、養毛効果をもつことは、いまだ知られて
いない。本発明書において「養毛効果」又は「養毛作用
」とは脱毛予防、毛体及び発毛の促進並びに育毛を怠味
する。However, it is not yet known that it has a hair-nourishing effect. In the present invention, the term "hair nourishing effect" or "hair nourishing effect" refers to prevention of hair loss, promotion of hair body and hair growth, and neglect of hair growth.
シアル酸並びにシアル酸誘導体の型造方法は合成法、天
然抽出法(原料:卵白、顎下腺ムチン、胎盤エキス、大
腸菌から得られるコロミン酸等)等が挙げられるが、安
価な点から乳原料抽出法(特許第1)91212、特許
第1252988、特開昭59−184197等)が特
に好ましい。Methods for molding sialic acid and sialic acid derivatives include synthetic methods and natural extraction methods (raw materials: egg white, submandibular gland mucin, placenta extract, colominic acid obtained from Escherichia coli, etc.); The extraction method (Patent No. 1) 91212, Patent No. 1252988, JP-A-184197, etc.) is particularly preferred.
以下に本発明に係る化合物の乳抽出法による製造例を示
す。乳抽出法で用いる乳は、牛乳、手孔、母乳その他自
由に選択でき、更に精製の度合により、シアル酸含有濃
度を調節できるので、用途、用法、剤型、目的に合わせ
て製造法を選択できるものである。尚、本発明はこれに
より限定されるものではない。An example of producing the compound according to the present invention by the milk extraction method will be shown below. The milk used in the milk extraction method can be freely selected from cow's milk, milk, breast milk, etc. Furthermore, the concentration of sialic acid can be adjusted depending on the degree of purification, so the manufacturing method can be selected according to the purpose, usage, dosage form, and purpose. It is possible. Note that the present invention is not limited to this.
(′M造例1)シアル酸
チーズホエー10tに塩酸28kgを添加してpHを2
に調節した後、92℃で60分間過熱して加水分解を行
った。得られたホエーの加水分解をスクリューデカンタ
−を用いて加熱により凝固したタンパク質を除去してシ
アル酸含有液を得た。次いで、シアル酸含有液を電解透
析装置の脱塩槽に入れて伝導度2 mS/ cmまで脱
塩した後、−旦透析を中止して濃縮槽液を廃棄した。次
いで濃縮槽に蒸留水301入れて再び伝導度50μS
/ c+nまで透析を行った。('M Example 1) Add 28 kg of hydrochloric acid to 10 tons of sialic acid cheese whey to adjust the pH to 2.
After adjusting the temperature, the mixture was heated at 92° C. for 60 minutes to perform hydrolysis. The resulting whey was hydrolyzed using a screw decanter to remove proteins coagulated by heating to obtain a sialic acid-containing liquid. Next, the sialic acid-containing solution was placed in a desalination tank of an electrodialyzer and desalted to a conductivity of 2 mS/cm, after which the dialysis was stopped and the concentration tank liquid was discarded. Next, put distilled water 301 into the concentration tank and increase the conductivity to 50μS again.
Dialysis was performed until /c+n.
透析終了後、濃縮槽液を濃縮・乾燥して白色粉末600
gを得た。このように得られた粉末の遊離シアル酸純度
は約97%であった。After dialysis, concentrate and dry the concentration tank liquid to obtain a white powder of 600%
I got g. The free sialic acid purity of the powder thus obtained was about 97%.
(実施例2)シアル酸塩
前述の′&離シアル酸を苛性ソーダで調整し、シアル酸
Naを得る。この他、Mg、 K、リン酸、アミノ酸塩
等自由に目的に応じて塩を選択し製造できる。(Example 2) Sialic acid salt The above-mentioned '& release sialic acid is prepared with caustic soda to obtain Na sialic acid. In addition, salts such as Mg, K, phosphoric acid, and amino acid salts can be selected and produced according to the purpose.
(製造例3)シアル酸結合オリゴ糖
牛乳或いはチーズホエーを限外濾過して調整した濾液を
、全固形20%まで減圧濃縮した。この液25Kgを電
気伝導度が20μS / cmになるまで電気透析した
後、ダウエックスIX2(2kg)を充填したカラムに
通じてオリゴ糖を吸着させた。次いで、このカラムに2
0kgの水を通じて、中性糖を除去した後、0.5M塩
酸を通じてカラムに吸着したオリゴ糖を溶出させた。得
られた溶出液のpHを30%苛性ソーダでpl+ 7.
0に調整後、再び電気伝導度が150μS/cn+にな
るまで電気透析した。得られた透析液を濃縮・乾燥して
白色粉末100gを得た。(Production Example 3) A filtrate prepared by ultrafiltrating sialic acid-bound oligosaccharide milk or cheese whey was concentrated under reduced pressure to a total solid content of 20%. After electrodialyzing 25 kg of this liquid until the electrical conductivity reached 20 μS/cm, it was passed through a column packed with DOWEX IX2 (2 kg) to adsorb oligosaccharides. Then add 2 to this column.
After removing neutral sugars through 0 kg of water, the oligosaccharides adsorbed on the column were eluted through 0.5 M hydrochloric acid. Adjust the pH of the obtained eluate to pl+ with 30% caustic soda.7.
After adjusting to 0, electrodialysis was performed again until the electrical conductivity reached 150 μS/cn+. The obtained dialysate was concentrated and dried to obtain 100 g of white powder.
このようにして得た粉末のシアル酸結合オリゴ糖純度は
90%であった。The purity of the sialic acid-bonded oligosaccharide of the powder thus obtained was 90%.
(製造例4)シアル酸結合タン白質
レンネットカゼインカード廃液30ONをフォードラタ
ンクで75℃、30分間加熱殺菌した後に、40℃まで
冷却し、濃塩酸でpl+を4.6に調整した。約30分
間静置し、沈澱を生成させた液をタラリファイヤーに通
しpl+を7.0に戻した後、清澄液をRO膜で濃縮、
脱塩した。10倍まで濃縮した後、濃縮液に水を加えて
再び10倍まで濃縮した。得られた濃縮液を乾燥して白
色粉末1.3kgを得た。このようにして得た粉末のシ
アル酸結合タン白質の純度は約80%あった。(Production Example 4) Sialic acid-bound protein rennet casein card waste liquid 30ON was heat sterilized at 75°C for 30 minutes in a Fordra tank, cooled to 40°C, and pl+ was adjusted to 4.6 with concentrated hydrochloric acid. After leaving to stand for about 30 minutes, the precipitate was passed through a talarifier to return the pl+ to 7.0, and the clarified solution was concentrated using an RO membrane.
Desalted. After concentrating up to 10 times, water was added to the concentrated solution and it was concentrated again up to 10 times. The obtained concentrate was dried to obtain 1.3 kg of white powder. The purity of the sialic acid-bound protein in the powder thus obtained was about 80%.
(製造例5)シアル酸結合脂質
バターミルク粉15kgにクロロホルム−メタノール混
液(1: 1)を100I!加え室温で30分間攪拌し
抽出した。次にクロロホルム−メタノール混液を回収し
イオン交換樹脂(DEAE−Toyopearlアセテ
ート型)lffに通じてシアル酸結合脂質を吸着させ、
次いでクロロホルム−メタノール混液(1:1)21で
樹脂を洗浄した後、0.5M酢酸ナトリウム−メタノー
ル溶液41でシアル酸結合脂質を溶出した。溶出液を濃
縮しメタノールを除去した後、水51を加えて限外濾過
で脱塩とシアル酸結合脂質の濃縮を行った。シアル酸結
合脂質を含む濃縮液をエバポレータで乾固した後、シリ
カゲルカラム(4,OX 50cm)に通じシアル酸結
合脂質を吸着させ、次いでクロロホルム1j2.クロロ
ホルム−メタノール混液(4:1)1βで順次洗浄した
後、クロロホルム−メタノール混液(2: 8)の混液
でシアル酸結合j脂質を溶出した。溶出液をエバポレー
タで蒸発乾固し白色粉末15gを得た。(Production Example 5) Add 100 l of chloroform-methanol mixture (1:1) to 15 kg of sialic acid-bound lipid buttermilk powder! The mixture was added, stirred at room temperature for 30 minutes, and extracted. Next, the chloroform-methanol mixture was collected and passed through an ion exchange resin (DEAE-Toyopearl acetate type) lff to adsorb sialic acid-bound lipids.
After washing the resin with a chloroform-methanol mixture (1:1) 21, the sialic acid-bound lipids were eluted with a 0.5M sodium acetate-methanol solution 41. After concentrating the eluate to remove methanol, water 51 was added and ultrafiltration was performed to desalt and concentrate the sialic acid-bound lipids. After the concentrated solution containing sialic acid-bound lipids was dried in an evaporator, it was passed through a silica gel column (4, OX 50cm) to adsorb the sialic acid-bound lipids, and then chloroform 1j2. After sequentially washing with 1β of a chloroform-methanol mixture (4:1), the sialic acid-bound J lipid was eluted with a mixture of chloroform-methanol (2:8). The eluate was evaporated to dryness using an evaporator to obtain 15 g of white powder.
このようにして得られた粉末のシアル酸結合脂質の純度
は薄層クロマトグラフィーで90%以上(レゾルシノー
ル法)であった。The purity of the sialic acid-bound lipid in the powder thus obtained was 90% or more (resorcinol method) as determined by thin layer chromatography.
次にシアル酸及びシアル酸誘導体の安全性試験を実施し
たので、その結果を示す。Next, safety tests were conducted on sialic acid and sialic acid derivatives, and the results are shown below.
急性毒性試験
製造例1〜5で製造したシアル酸、シアル酸Na、シア
ル酸結合オリゴ糖、シアル酸結合タン白、シアル酸結合
脂質各々を被験物質として、ICR系雌性マウス(6週
齢、1群5匹)を用い、腹腔的投与は0.5%カルボキ
シメチルセルロースナトリウム/生理食塩液に各被験物
質2重量%となるようにIg濁させたものを221/2
Gの注射針を使用して、又、経口投与はオリーブ油に
各被験物質5重量%となるように懸濁させたものを経口
針を使用して、腹腔的投与は60J/kg、経口投与は
3〇−/kgを与えた。その結果、全部の被験物質につ
いて70間の観察期間中に死亡例、体重の減少及び特記
すべき中毒症状は認められず、また7日日に行った剖検
においても何等異常は認められなかった。Acute toxicity test ICR female mice (6 weeks old, For intraperitoneal administration, Ig 221/2 of each test substance was suspended in 0.5% sodium carboxymethylcellulose/physiological saline to a concentration of 2% by weight.
For oral administration, use a suspension of each test substance at 5% by weight in olive oil using an oral needle; for intraperitoneal administration, use 60 J/kg; for oral administration, 30-/kg was given. As a result, no deaths, no decreases in body weight, and no noteworthy toxic symptoms were observed during the 70-year observation period for all test substances, and no abnormalities were observed in the autopsy performed on the 7th day.
この結果から明らかなようにシアル酸及びシアル酸誘導
体の急性毒性値(LD50)は、腹腔的投与で1200
■/kg以上、経口投与で1500mg / kg以上
であり、安全性が高いことが判明した。As is clear from these results, the acute toxicity value (LD50) of sialic acid and sialic acid derivatives is 1200 when administered intraperitoneally.
It was found to be highly safe, with an oral dose of 1500 mg/kg or more.
次にシアル酸及びシアル酸誘導体を養毛剤として適用す
るための製剤化について述べる。Next, the formulation of sialic acid and sialic acid derivatives for use as a hair nourishing agent will be described.
本発明の養毛剤は、シアル酸、シアル酸誘導体の他に、
製薬上、許容することのできる添加剤及びその他の薬剤
を加えた混合物の形で使用できる。In addition to sialic acid and sialic acid derivatives, the hair tonic of the present invention also includes:
It can be used in a mixture with pharmaceutically acceptable excipients and other agents.
但し、シアル酸は酸、アルカリ、光に対しての安定性に
問題があり、長期保存に適さないため安定性の良いシア
ル酸誘導体を用いた方が好ましい。However, sialic acid has problems with stability against acids, alkalis, and light, and is not suitable for long-term storage, so it is preferable to use sialic acid derivatives with good stability.
前記の添加剤としては、例えば、塩化カルプロニウム、
ミノキシジル、ジアヅキザイド等の血管拡張剤、エスト
ラジオール等の女性ホルモン剤、メチオニン等のアミノ
酸類、ビタミンB群等のビタモン類、冬虫夏草等の生薬
類、ペンタデカン酸、及びこれらのトリグリセリド類等
の皮Iiv機能冗進剤、オキセンドロン等の抵男性ホル
モン刑、ヒノキチオール、ヘキサクロロフェン、フェノ
ール、ZPT、 トコフエリルレチノエート、ビタミ
ンE・ニコチン酸エステル、ビタミンE・酢酸エステル
、硫化セレン、チオキソロン、イオウ、レゾルシン、テ
トラクロロサリチルアニリド、オクタデシルY・リメチ
ルアンモニウムクロリド、ヘキサデ′シルジメチルベン
ジルアンモニウムクロリド等の第4級アンモニウム塩、
塩化ベンザルコニウム、セチルピリジニウムクロリド、
ウンデシレン酸、トリクロロカルバニリド及びビチオノ
ール等の抗フケ剤、グリチルリチン酸及びそのアンモニ
ウム塩等の誘導体、アラントイン、メントール等の消炎
或は清涼剤、サリチル酸、亜鉛及びその化合物、乳酸及
びそのアルキルエステル、ビタミン類、生薬成分等の薬
剤、オリーブ油、マカデミアナツツ油、スクヮラン等の
動植物油、流動パラフィンに代表される炭化水素油、イ
ソプロピルミリステート、セチルイソオクタノエート、
2−エチルへキシルパルミテート等のエステル油、ミツ
ロウ等のワックス類、高級脂肪酸、高級アルコール等の
油分、水、乳酸及びそのエチルエステル等の誘導体、ポ
リエチレングリコール、ソルビトール等の多価アルコー
ル、エタノール等の低級アルコール、ムコ多糖類(コン
ドロイチン硫酸、ヒアルロン酸及びそれらの塩等)、ピ
ロリドンカルボン酸塩、プロテオグリカン、コラーゲン
、グリセリン等の保湿剤、界面活性剤、香料、酸化防止
剤、紫外線吸収剤、色素等を挙げることができ、これら
を一種又は二種以上混合して使用する。Examples of the additive include carpronium chloride,
Vasodilators such as minoxidil and diadukizide, female hormones such as estradiol, amino acids such as methionine, vitamins such as B vitamins, herbal medicines such as Cordyceps sinensis, pentadecanoic acid, and their triglycerides, etc. Anti-androgen drugs such as oxendrone, hinokitiol, hexachlorophene, phenol, ZPT, tocopheryl retinoate, vitamin E/nicotinic acid ester, vitamin E/acetate, selenium sulfide, thioxolone, sulfur, resorcinol, tetrachlorosalicyl anilide, quaternary ammonium salts such as octadecyl Y.limethylammonium chloride, hexade'sildimethylbenzylammonium chloride,
Benzalkonium chloride, cetylpyridinium chloride,
Anti-dandruff agents such as undecylenic acid, trichlorocarbanilide and bithionol, derivatives such as glycyrrhizic acid and its ammonium salts, anti-inflammatory or cooling agents such as allantoin and menthol, salicylic acid, zinc and its compounds, lactic acid and its alkyl esters, vitamins drugs such as crude drug ingredients, animal and vegetable oils such as olive oil, macadamia nut oil, and squalane, hydrocarbon oils such as liquid paraffin, isopropyl myristate, cetyl isooctanoate,
Ester oils such as 2-ethylhexyl palmitate, waxes such as beeswax, oils such as higher fatty acids and higher alcohols, water, derivatives such as lactic acid and its ethyl ester, polyhydric alcohols such as polyethylene glycol and sorbitol, ethanol, etc. Lower alcohols, mucopolysaccharides (chondroitin sulfate, hyaluronic acid and their salts, etc.), pyrrolidone carboxylates, proteoglycans, collagen, humectants such as glycerin, surfactants, fragrances, antioxidants, ultraviolet absorbers, pigments. These can be used singly or in combination of two or more.
本発明の養毛剤の剤型は、薬効を得るに適したものであ
れば任意の形態が使用でき、例えば、粉末、顆粒、散剤
、錠剤、カプセル剤、シロップ剤、座剤、注射剤、軟膏
剤等である。この中で外用剤が使用簡便な点から好まし
く、外用できるものであれば任官の形態でよく、例えば
、ローション、リニメント、乳液等の外用液剤、クリー
ム、軟膏、パスタ、パップ、ゼリー、スプレー等の外用
半固型剤等を挙げることができる。The hair growth agent of the present invention can be in any form as long as it is suitable for obtaining medicinal effects, such as powder, granules, powder, tablets, capsules, syrups, suppositories, injections, and ointments. etc. Among these, external preparations are preferred from the point of view of ease of use, and may be in the official form as long as they can be applied externally.For example, external preparations such as lotions, liniments, milky lotions, creams, ointments, pasta, poultices, jellies, sprays, etc. Semi-solid preparations for external use can be mentioned.
本発明の養毛剤には、有効成分であるシアル酸並びにシ
アル酸誘導体全量の配合量は、組成物全9に対してo、
ooot〜50重口%、好ましくはo、ooi〜5m1
%である。0.0001正量%未満では充分な効果が得
られに(い傾向にあり、逆に50重量%を越えても効果
の大きな増大を望むことは難しい。In the hair growth agent of the present invention, the total amount of sialic acid and sialic acid derivatives as active ingredients is o,
ooot ~ 50% by weight, preferably o, ooi ~ 5ml
%. If it is less than 0.0001% by mass, sufficient effects tend to be difficult to obtain, and conversely, even if it exceeds 50% by weight, it is difficult to expect a significant increase in the effect.
本発明の養毛剤は、外用の場合は、皮膚に直接塗布又は
散布する経皮投与による投与方法をとる。When the hair tonic of the present invention is used externally, it is administered by transdermal administration, in which it is directly applied or sprayed on the skin.
又、本発明の養毛剤の投与量は、年翻、個人差、病状等
によって下記範囲外の量を投与することもあり得るので
即離には限定できないが一般に人を対象とする場合、シ
アル酸又はシアル酸誘導体全量の内服及び経皮投与量は
、体ff1)Kg及び1日あたり 0.001〜200
0mg1好ましくは、0.01〜1000mgであり、
この量を一口に1回又は数回にわけて投与することがで
きる。In addition, the dosage of the hair tonic of the present invention cannot be limited to immediate hair removal as it may be administered in an amount outside the following range depending on age, individual differences, medical conditions, etc. Or the total amount of the sialic acid derivative for oral administration and transdermal administration is 0.001 to 200 per kg of body ff1) per day.
0 mg1 preferably 0.01 to 1000 mg,
This amount can be administered once or in several doses.
以下に実施例を示して本発明による養毛剤の製剤化方法
及′び養毛効果を具体的に説明する。尚、本発明はこれ
により限定されるものではない。以下、配合量は重囲%
である。The method for formulating the hair growth agent and the hair growth effect according to the present invention will be specifically explained below with reference to Examples. Note that the present invention is not limited to this. Below, the compounding amount is % weight
It is.
(養毛剤の製造方法)
95%エタノールにシアル酸Na及び硬化ヒマシ油エチ
レンオキシド(40モル)付加物を添加し、攪拌溶解さ
せ、次いでイオン交換水を添加、混合して、実施例1の
液状養毛剤を得た。実施例2〜5並びに比較例1も実施
例1と同様にして得た。使用したシアル酸Na並びにシ
アル酸誘導体は、製造例2〜5で製造したものである。(Method for producing a hair tonic) Na sialic acid and hydrogenated castor oil ethylene oxide (40 mol) adduct were added to 95% ethanol, stirred and dissolved, and then ion-exchanged water was added and mixed to produce the liquid hair tonic of Example 1. Obtained. Examples 2 to 5 and Comparative Example 1 were also obtained in the same manner as Example 1. The Na sialic acid and sialic acid derivatives used were those produced in Production Examples 2 to 5.
表−1実施例1〜5並びに比較例1の処方(養毛効果試
験)
次に本発明の養毛剤の養毛効果を調べるため、(J)ト
リコグラム試験、(2)路上転換率試験を実施例1〜5
及び比較例1の養毛剤について行った。Table 1: Prescriptions of Examples 1 to 5 and Comparative Example 1 (hair growth effect test) Next, in order to investigate the hair growth effect of the hair growth agent of the present invention, (J) Trichogram test and (2) Road conversion rate test were conducted. Examples 1-5
and the hair growth agent of Comparative Example 1.
(1)トリコグラム試験
養毛剤の使用前と使用後の抜去毛髪の毛根を顕微鏡下で
観察し、毛根の形態から休止期毛根数を計数し、その割
合の増減によって養毛剤の養毛効果を比較した。休止期
毛根とは成長の止まった毛の毛根であり、脱毛を訴える
人は正常な人よりもこの休止期毛根の割合が多いので、
この休止期毛根の減少から養毛効果を評価した。(1) Trichogram test The removed hair roots were observed under a microscope before and after using the hair tonic, and the number of hair roots in the resting phase was counted from the morphology of the hair roots, and the hair growth effect of the hair tonic was compared by increasing or decreasing the percentage. . Telogen hair roots are hair roots that have stopped growing, and people who complain of hair loss have a higher proportion of hair roots in the resting stage than normal people.
The hair-nourishing effect was evaluated based on the decrease in the number of telogen hair roots.
実施例1〜5及び比較例1の各養毛剤試験液をそれぞれ
男性被験者10名の頭皮に1日2回、1回2−ずつ6力
月間連続して塗布し、塗布直前及び6力月間塗布終了直
後に被験者1名につき 100本ずつ毛髪を除去し、そ
れぞれの毛根を調べた。養毛剤使用前に対する使用後の
休止期毛根の割合の変化率を求め、15%以上減少した
場合を有効例とし、を効率を求めた。結果を表−2に示
した。Each of the hair tonic test solutions of Examples 1 to 5 and Comparative Example 1 was applied to the scalps of 10 male subjects twice a day, 2 times a day, for 6 consecutive months, immediately before application, and after the end of the 6 month application. Immediately after, 100 hairs were removed from each subject and each hair root was examined. The rate of change in the percentage of telogen hair roots after use compared to before use of the hair tonic was determined, and a case where the percentage decreased by 15% or more was taken as an effective example, and the efficiency was determined. The results are shown in Table-2.
表−2トリコグラム試験結果
(2)路上転換率試験
男性型脱毛症の被験者30名の各々の頭部うぶ毛部位3
か所において、前記の各試験液(実施例1〜5及び比較
例1)の塗布前後における、うぶ毛から路上への転換率
を比較した。路上とはうぶ毛以外の毛、すなわち長さ1
4m以上の毛をいい、うぶ毛から路上への転換は養毛効
果を意味する。1群5名の6群に分け、1群ごとに各試
験液を1日2回(朝、晩)、4力月間頭部全体に塗布し
た。Table 2 Trichogram test results (2) On-road conversion rate test Three down hair sites on the head of each of the 30 subjects with androgenetic alopecia
At different locations, the conversion rate from downy hair to road surface was compared before and after application of each of the test solutions (Examples 1 to 5 and Comparative Example 1). On the street, hair other than downy hair, that is, length 1
It refers to hair that is 4 meters or longer, and the transition from downy hair to street hair means a hair-nourishing effect. The subjects were divided into 6 groups of 5 people per group, and each test solution was applied to the entire head of each group twice a day (morning and evening) for 4 months.
各試験液の塗布直前及び4力月塗布直後に、前記の頭部
うぶ毛部位を接写写真撮形して転換率を測定し、路上へ
の転換率は3カ所の平均をパーセントで示した。養毛効
果の判定は、平均路上転換率%10以上を有効とし、1
0%未満を無効と判断した。Immediately after the application of each test solution and immediately after the application of the 4 months, close-up photographs were taken of the above-mentioned down hair sites on the head to measure the conversion rate, and the conversion rate to the road was expressed as a percentage of the average of the three locations. To judge the hair growth effect, an average on-road conversion rate of 10% or more is considered effective, and 1
Less than 0% was judged as invalid.
表−3路上転換率試験結果
(結果)
表−2,3の試験結果から、シアル酸並びにシアル酸誘
導体に優れた養毛効果があり、又、シアル酸並びにシア
ル酸誘導体を二種以上組合わせると相乗効果が得られる
ことも認められた。尚、両試験において、副作用をうっ
たえる被験者はゼロで、且つフケ、カユミが抑まったと
言う被験者が多かったことから、安全性の高い養毛剤で
あることが判明した。Table-3 On-road conversion rate test results (results) From the test results in Tables-2 and 3, sialic acid and sialic acid derivatives have excellent hair-nourishing effects, and combinations of two or more types of sialic acid and sialic acid derivatives It was also recognized that a synergistic effect could be obtained. In both tests, no subjects complained of side effects, and many subjects said that dandruff and itching had been suppressed, indicating that it was a highly safe hair growth agent.
次に各種実施態様を示す。以下、配合量は重量%とする
。Next, various embodiments will be shown. Hereinafter, the blending amount is expressed as weight %.
実施例6 W10乳化型養毛剤 (重量%)ポ
リオキシエチレン(60モル)
付加硬化ヒマシ油 2.0
グリセリン 10.0ジプロピレ
ングリコール 10.01.3−ブチレン
グリコール 5,0ポリエチレングリコール1
500 5.0セチルイソオクタネート
10.0スクワラン
5.0ワセリン 2.
0プロピルパラベン 2.0カルボ
キシビニルポリマー
へキサメタリン酸ソーダ 0.03カセイ
カリ 0.12シアル酸Na
1.0イオン交換水
残余実施例7 クリーム状養毛
剤 (重量%)シアル酸結合オリゴ糖
5.0シアル酸結合タン白
2.0シアル結合脂質 0.00
01流動パラフイン 5.0セト
ステアリルアルコール 5.5グリセリルモ
ノステアレート 3.OIEO(20モル)−
2−
オクチルドデシルエーテル 3.0
プロピルパラベン 0.3香料
0.1グリセリン
8.0ジプロピレングリコール
20.0ポリエチレングリコール4000
5.0へキサメタリン酸ソーダ
0.005イオン交換水
残余実施例8 錠剤
、シアルfiJ.C a 50mg,シアル酸結合オリ
ゴ糖50mg、シアル酸結合脂質50mg、シアル酸結
合タン白50mgと微結晶セルロース100n+gとを
含有する錠剤を常法に従って調整し、シロップゼラチン
沈降性炭酸カルシウムで糖衣をほどこした。この錠剤は
1回の投与量1〜10錠で使用される。Example 6 W10 emulsified hair tonic (% by weight) Polyoxyethylene (60 mol) Addition hydrogenated castor oil 2.0 Glycerin 10.0 Dipropylene glycol 10.0 1.3-Butylene glycol 5,0 Polyethylene glycol 1
500 5.0 Cetyl Isooctanate
10.0 Squalane
5.0 Vaseline 2.
0 Propyl paraben 2.0 Carboxy vinyl polymer hexametaphosphate Sodium 0.03 Caustic potash 0.12 Sodium sialic acid
1.0 ion exchange water
Remaining Example 7 Cream-like hair nourishing agent (wt%) Sialic acid-bonded oligosaccharide
5.0 sialic acid binding protein
2.0 Sial-linked lipid 0.00
01 Liquid paraffin 5.0 Cetostearyl alcohol 5.5 Glyceryl monostearate 3. OIEO (20 mol) -
2- Octyl dodecyl ether 3.0 Propylparaben 0.3 Fragrance
0.1 glycerin
8.0 Dipropylene glycol 20.0 Polyethylene glycol 4000
5.0 Sodium hexametaphosphate
0.005 ion exchange water
Remaining Example 8 Tablets, Cial fiJ. A tablet containing 50 mg of C a , 50 mg of sialic acid-bound oligosaccharide, 50 mg of sialic acid-bound lipid, 50 mg of sialic acid-bound protein and 100 n+g of microcrystalline cellulose was prepared according to a conventional method, and sugar-coated with syrup gelatin precipitated calcium carbonate. Ta. This tablet is used in a single dose of 1 to 10 tablets.
実施例9 顆粒剤
シアル酸結合オリゴ糖20gと乳糖80g、水10gお
よび微結晶セルロース90gを均一混合し、破砕造粒し
、乾燥、篩別して顆粒剤を得た。この顆粒剤は1回の投
与量0.5〜10gで使用される。Example 9 Granules 20 g of sialic acid-bonded oligosaccharides, 80 g of lactose, 10 g of water and 90 g of microcrystalline cellulose were uniformly mixed, crushed, granulated, dried and sieved to obtain granules. This granule is used in a single dose of 0.5 to 10 g.
実施例10 カプセル剤
シアル酸結合タン白 100nwと微結晶セルロース1
00■および乳糖200■を均一混合。このカプセル剤
は1回の投与i1〜10カプセルで使用される。Example 10 Capsule sialic acid-bound protein 100nw and microcrystalline cellulose 1
00■ and lactose 200■ are uniformly mixed. The capsules are used in a single dose of 1 to 10 capsules.
実施例1) 軟介
流動パラフィン(95%)とポリエチレン(5%)より
成るプラスチヘース50W 47.5gにシアル酸結
合オリゴ糖2.5gを練合し、減圧脱気して軟膏:y゛
を得た。この軟膏は1日4〜5回幹部に塗布される。Example 1) 2.5 g of sialic acid-bonded oligosaccharide was kneaded with 47.5 g of Plastihose 50W consisting of soft liquid paraffin (95%) and polyethylene (5%), and the mixture was degassed under reduced pressure to obtain an ointment: y゛. Ta. This ointment is applied to the trunk 4-5 times a day.
本発明の養毛剤は安全性が高り、優れた育毛、脱毛予防
、フうー・カユミ抑制効果をもつ養毛剤である。The hair growth agent of the present invention is highly safe and has excellent effects on hair growth, hair loss prevention, and suppressing itchiness and itchiness.
特許出願人 株式会社 資 生 堂 雪印乳業株式会社Patent applicant: Shiseido Co., Ltd. Snow Brand Milk Products Co., Ltd.
Claims (4)
された一種又は二種以上を含有してなる養毛剤。(1) A hair nourishing agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
酸結合タン白、シアル酸結合脂質並びにシアル酸塩であ
る特許請求の範囲第(1)項記載の養毛剤。(2) The hair growth agent according to claim (1), wherein the sialic acid derivative is a sialic acid-bonded oligosaccharide, a sialic acid-bonded protein, a sialic acid-bound lipid, or a sialic acid salt.
導体を用いる特許請求の範囲第(1)項又は第(2)項
記載の養毛剤。(3) The hair growth agent according to claim (1) or (2), which uses sialic acid or a sialic acid derivative obtained by extraction from milk.
請求の範囲第(1)項、第(2)項又は第(3)項記載
の養毛剤。(4) The hair tonic according to claim (1), (2) or (3), wherein the sialic acid is N-acetylneuraminic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32357087A JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32357087A JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01163114A true JPH01163114A (en) | 1989-06-27 |
JP2555389B2 JP2555389B2 (en) | 1996-11-20 |
Family
ID=18156176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32357087A Expired - Lifetime JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2555389B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679645A (en) * | 1993-07-23 | 1997-10-21 | Snow Brand Milk Products Co., Ltd. | Sialic acid powder and process for the preparation thereof |
JP2010006844A (en) * | 2007-08-27 | 2010-01-14 | Iriya Cosmetics Co Ltd | Secretagogue for insulin-like growth factor-1 |
JPWO2009144977A1 (en) * | 2008-05-28 | 2011-10-06 | 研二 岡嶋 | Oral hair growth composition |
WO2012053849A2 (en) * | 2010-10-20 | 2012-04-26 | 주식회사 베네비오 | Depilatory composition |
CN103655218A (en) * | 2013-11-14 | 2014-03-26 | 无锡西玛生物科技有限公司 | Hair growth shampoo |
CN104146885A (en) * | 2014-07-14 | 2014-11-19 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid hydrate in hair care product |
US10543159B2 (en) | 2014-11-20 | 2020-01-28 | Ezaki Glico Co., Ltd. | Hair papilla cell activator |
-
1987
- 1987-12-21 JP JP32357087A patent/JP2555389B2/en not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679645A (en) * | 1993-07-23 | 1997-10-21 | Snow Brand Milk Products Co., Ltd. | Sialic acid powder and process for the preparation thereof |
JP2010006844A (en) * | 2007-08-27 | 2010-01-14 | Iriya Cosmetics Co Ltd | Secretagogue for insulin-like growth factor-1 |
JPWO2009144977A1 (en) * | 2008-05-28 | 2011-10-06 | 研二 岡嶋 | Oral hair growth composition |
WO2012053849A2 (en) * | 2010-10-20 | 2012-04-26 | 주식회사 베네비오 | Depilatory composition |
WO2012053849A3 (en) * | 2010-10-20 | 2012-09-13 | 주식회사 베네비오 | Depilatory composition |
CN103655218A (en) * | 2013-11-14 | 2014-03-26 | 无锡西玛生物科技有限公司 | Hair growth shampoo |
CN104146885A (en) * | 2014-07-14 | 2014-11-19 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid hydrate in hair care product |
US10543159B2 (en) | 2014-11-20 | 2020-01-28 | Ezaki Glico Co., Ltd. | Hair papilla cell activator |
Also Published As
Publication number | Publication date |
---|---|
JP2555389B2 (en) | 1996-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2769246T3 (en) | Composition comprising D-mannoheptulose and / or perseitol for the treatment or prevention of diseases related to a modification of innate and / or acquired immunity | |
JP4995078B2 (en) | A medicament comprising a peptide extract of avocado for use in the treatment and prevention of diseases associated with immune system failure | |
KR100929264B1 (en) | External skin preparation | |
US8652543B2 (en) | Cosmetic and/or pharmaceutical compositions and their applications | |
US20080108681A1 (en) | Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions | |
BRPI0802515B1 (en) | cosmetic use and use of at least one vitreoscilla filiformis bacterial extract, composition and non-therapeutic cosmetic treatment process | |
JP4252460B2 (en) | Skin preparation for external use | |
JP2557240B2 (en) | Skin anti-aging agent | |
JP4430770B2 (en) | Skin elasticity improver | |
JPH01163114A (en) | Hair tonic | |
JP2684179B2 (en) | Anti-inflammatory agent | |
JPH05262635A (en) | Dermatic external preparation | |
JP5669437B2 (en) | Composition | |
JP2557241B2 (en) | Anti-pigmenting agent | |
JP2011241166A5 (en) | ||
JPH10175868A (en) | Water (of chinese medicine idea) improving composition | |
JPH03112912A (en) | Cosmetic composition | |
EP4021587A1 (en) | Skin care composition comprising mevalonolactone | |
CN106913515B (en) | Taurine-chelated calcium external preparation for reestablishing skin barrier steady state and application thereof | |
JP2013144651A (en) | Keratin production promoter, food, skin external preparation, and hair restorer | |
JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
US20220331219A1 (en) | Methods and compositions for providing skin care benefits | |
JP2011207816A (en) | Collagen production promoter | |
CN115813839A (en) | Traditional Chinese medicine cosmetic composition for moisturizing, resisting aging and brightening skin and preparation method thereof | |
WO2019175364A1 (en) | A treatment composition |